EARNING RECAP

Regeneron Pharmaceuticals Inc

#REGN 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q1 $4.45 est. $5.46 $1.71B est. $1.76B -6.34% ($322.40 closing price) $336.50 $318.70 Q1 Eylea injections U.S. sales 1.07B; Libtayo U.S. sales $27M
#REGN 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 $6.84 est. $5.78 $1.93B est. $1.71B -3.44% ($406.56 closing price) $429.90 $406.40 Q4 U.S. Eylea sales $1.08B; Libtayo injections $15M
Q3 $5.87 est. $5.13 $1.66B est. $1.64B +.75% ($357.61 closing price) $367 $349.59 Q3 Eylea global net sales up 11% to $1.68B, in U.S. $1.022B
Q2 $5.45 VS $4.70 $1.61B VS $1.56B +7.00% $401.50 $$367.52 Eylea global net sales up 13% to $1.66b
Q1 $4.67 VS $4.38 $1.51B vs $1.51B -1.26% $307.72 $288.16 Narrow FY CapEx view to $420-$480M from $420-$500M
#REGN 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 $5.23 VS $4.53 $1.58b VS $1.5b -3.58% $352.50 $322.02 Dupixent sales $146M vs $122m
Q3 $3.99 est. $3.85 $1.5B est. $1.46B. +2.67% close at $$415.17 $432.50 $405.00 Q3 EYLEA U.S. net product sales $953M.
Q2 $4.17 vs. $3.17 $1.47B vs. $1.35B -2.04% closed at $467.11 $498.50 $463.30 +4.9% initial reaction on Q2 release
Q1 $2.92 Vs $3.07 $1.32B Vs $1.30B +6.70% @ $434.31 $437.32 $410.19 FY17 Eylea U.S. sales view of single digit percentage growth. Reaction dips buyers

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.